RegenxBio Inc. just locked in another deal — this one with a company working to treat eye diseases.
The Rockville biotech has reached a licensing agreement with Alpharetta, Georgia-based Clearside Biomedical Inc. (NASDAQ: CLSD) for rights to its platform to treat several eye diseases including wet age-related macular degeneration and diabetic retinopathy. RegenxBio (NASDAQ: RGNX) plans to evaluate one of its own gene therapy programs, called RGX-314, using Clearside’s in-office injection as an alternative to surgery.
{iframe}https://www-bizjournals-com.cdn.ampproject.org/c/s/www.bizjournals.com/washington/news/2019/09/09/this-rockville-biotech-has-added-another-deal-to.amp.html{/iframe}